Oragenics, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; comparisons are with FY2020. Oragenics is a development-stage biotechnology company with no commercial product revenue. Its lead program is the preclinical intranasal COVID-19 vaccine candidate NT-CoV2-1; it also conducts early-stage lantibiotic antibiotic research.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Grant revenue | $86,987 | $0 |
| Research and development expense | $10.59 million | $22.11 million |
| General and administrative expense | $5.27 million | $4.53 million |
| Net loss | $15.71 million | $26.43 million |
| Net loss per share, basic and diluted | $0.14 | $0.47 |
| Cash used in operating activities | $13.47 million | $16.95 million |
| Cash and cash equivalents at year-end | $27.27 million | $17.64 million |
| Working capital | $26.26 million | $16.64 million |
Product sales were not reported. Product gross margins therefore are not meaningful. The company reported an accumulated deficit of $171.27 million and shareholders’ equity of $26.49 million at year-end. Short-term notes payable were $303,416; current and long-term operating lease liabilities totaled $493,790. The filing reports no off-balance-sheet arrangements.
Financing provided $23.14 million of net cash in FY2021, principally through an at-the-market offering that raised approximately $27.8 million gross, warrant exercises, and option exercises. The company also paid approximately $5.64 million to redeem its Series C preferred stock. Common shares outstanding rose from 91.77 million at year-end 2020 to 116.39 million at year-end 2021.
Material changes versus FY2020
- Net loss narrowed by approximately $10.72 million. R&D expense fell 52%, primarily because FY2020 included the $9.96 million Noachis Terra acquisition charge and other program costs; vaccine-program spending increased by approximately $4.79 million in FY2021.
- G&A expense increased 16%, mainly due to higher non-employee stock compensation, filing, board, and insurance costs.
- Operating cash use declined by approximately $3.48 million. Year-end cash increased by $9.63 million, supported by equity financing.
- The company and Eleszto Genetika mutually terminated their lantibiotic collaboration in September 2021. Oragenics stopped developing OG716 and related compounds under that agreement and retained its own intellectual property.
Programs, outlook, and key risks
- NT-CoV2-1: Management selected the intranasal candidate for further development, citing potential mucosal immunity, reduced transmission, and needle-free administration. Reported animal studies showed immune responses and reduced viral loads to undetectable levels in hamsters five days after challenge; these are preclinical findings, not evidence of human safety or efficacy. A rabbit toxicology study was initiated.
- Guidance: The company expected to submit an FDA IND in Q3 2022 and, if authorized, begin a Phase 1 study. Further development was dependent on additional funding, grants, partnerships, or out-licensing. Management expected existing resources to fund operations through Q4 2022.
- Lantibiotics: The company plans to identify new candidates and continue manufacturing and preclinical work, subject to available capital. A $250,000 SBIR grant supports research on lantibiotics targeting ESKAPE pathogens; $86,987 was recognized as grant revenue in 2021.
- Going concern: The auditor issued an unqualified opinion on the financial statements but included an explanatory paragraph stating that recurring losses, negative operating cash flows, and the accumulated deficit raise substantial doubt about the company’s ability to continue as a going concern. The company stated that additional financing would be required and might not be available on acceptable terms.
- Execution and funding risks: Both lead programs remain preclinical; no product has been approved, and the company has not initiated a vaccine clinical trial. Development depends on third-party manufacturers and contractors, regulatory approvals, successful studies, and further financing. Equity financing may dilute shareholders.
- Competition and rights: The COVID-19 vaccine market is highly competitive, and demand could shift with variants, competing vaccines, or the course of the pandemic. NIH and NRC licenses are nonexclusive; NIH-licensed patent applications had not issued as of the filing. License obligations include development milestones, royalties, and manufacturing-related requirements.
- Subsequent events: In February 2022, shareholders approved increasing authorized common shares from 200 million to 250 million and approved the 2021 Equity Incentive Plan. In March 2022, the company reported entering a KBI Biopharma agreement for process transfer, optimization, and planned Phase 2 manufacturing, creating payment obligations if timing changes or the agreement is canceled.
Investor facts to verify
- Current cash runway, cash burn, and the status and terms of any financing, grant, partnering, or out-licensing plans.
- Whether the IND was submitted and authorized, and the status, funding, and timing of the proposed Phase 1 trial and required toxicology work.
- Whether animal-study findings are reproducible and translate into human safety, efficacy, and reduced transmission.
- Manufacturing readiness, KBI commitments, potential delay or cancellation costs, and the impact of NIH/NRC license requirements.
- Potential dilution from future equity issuance, outstanding warrants and options, preferred-stock conversion, and the increased share authorization.
- Progress toward new lantibiotic candidates and the extent to which the $250,000 grant supports the program beyond the current research stage.